The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Tislelizumab is now approved in nine indications in China
Company hires life science veteran Jessica Cao to join management team
We have grown from $10 billion to $80 billion. India is not too far from reaching the league of top-10 countries in Biotech's global ecosystem”
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
This MoU will further strengthen relations between India and the USA within the framework of international scientific and technological cooperation in fields of mutual interest.
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
Subscribe To Our Newsletter & Stay Updated
